[Federal Register Volume 69, Number 79 (Friday, April 23, 2004)]
[Notices]
[Page 22055]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 04-9239]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[Program Announcement 04084]


Development and Testing of New Antimalarial Drugs; Notice of 
Intent To Fund Single Eligibility Award

A. Purpose

    The Centers for Disease Control and Prevention (CDC) announces the 
intent to fund fiscal year (FY) 2004 funds for a cooperative agreement 
program to support research projects to develop and test new 
antimalarial drugs. The Catalog of Federal Domestic Assistance number 
for this program is 93.283.

B. Eligible Applicant

    Assistance will be provided only to the University of Mississippi. 
The FY 2000 United States Senate Labor-Health and Human Services 
Appropriations Report: Report 106-166 (S 1650), recognized the unique 
qualifications of the consortium headed by the University of 
Mississippi School of Pharmacy, that includes the Department of 
Medicinal Chemistry the Laboratory for Applied Drug Design and 
Synthesis, the Thad Cochran Center for Natural Products, the Tulane 
University Center for Infectious Diseases and the Tulane National 
Primate Research Center for carrying out the activities specified in 
this cooperative agreement and directed CDC to provide research funding 
to the consortium. These organizations in the past three years have 
worked in a unique partnership through a CDC cooperative agreement to 
analyze and use natural products as antimalarial agents, set-up state 
of the art chemical synthesis and organic product laboratories, refine 
lead drug candidates and target molecules, conduct and organize phase I 
and II clinical trials, and conduct in-vitro and in-vivo therapeutic 
evaluations of drug activities and efficacies. No other consortia of 
this type or identity as headed by the University of Mississippi School 
of Pharmacy exists at this time in the public/academic realm that has 
all these elements working together as a unit, which is necessary to 
conduct rationale drug development. House Report 108-401 directed the 
continuation of this work in FY 2004. The project supports the ongoing 
activities of CDC in the global control and prevention of malaria and 
the goals to protect Americans from infectious diseases and reduce the 
spread of anti-microbial resistance.

C. Funding

    Approximately $5,000,000 is available in FY 2004 to fund this 
award. It is expected that the award will begin on or before August 1, 
2004, and will be made for a 12-month budget period within a project 
period of up to five years. Funding estimates may change.

D. Where To Obtain Additional Information

    For general comments or questions about this announcement, contact: 
Technical Information Management, CDC Procurement and Grants Office, 
2920 Brandywine Road, Atlanta, GA 30341-4146, telephone: 770-488-2700.
    For technical questions about this program, contact: John W. 
Barnwell, Ph.D., MPH, Project Officer, 4770 Buford Highway, Atlanta, GA 
30341, telephone: 770-488-4528, e-mail: [email protected].

    Dated: April 19, 2004.
William P. Nichols,
Acting Director, Procurement and Grants Office, Centers for Disease 
Control and Prevention.
[FR Doc. 04-9239 Filed 4-22-04; 8:45 am]
BILLING CODE 4163-18-P